Save time and get answers to complex questions with AI chat
Xenazine current manufacturer 2025?Guselkumab patent expiration?Sun pharma bortezomib?How does iron rich food intake impact lipitor's efficacy?Patent term adjustment semaglutida?
See the DrugPatentWatch profile for Synjardy
Synjardy 5 / 1000 (5 mg empagliflozin + 1000 mg metformin)
Synjardy is a fixed‑dose combination tablet that contains metformin (an oral biguanide) and empagliflozin (an SGLT‑2 inhibitor). It’s approved for adults with type 2 diabetes mellitus (T2DM) as part of a comprehensive treatment plan that includes diet, exercise, and weight management.
The 5 / 1000 version is less common than the 10 / 500 or 10 / 1000 combinations, but it can be prescribed in certain clinical situations—e.g., when a patient needs a lower empagliflozin exposure (perhaps due to kidney function, drug interactions, or side‑effect profile) but still requires a high metformin dose.
Always consult your healthcare provider before making any changes to your diabetes regimen.
Other Questions About Synjardy :